Gene Editing Nears an End to Daily Cholesterol Meds
A new one-time CRISPR treatment targeting “bad” cholesterol will enter Phase I human trials. If it works, it could become the first approved gene-silencing therapy, removing the need for lifelong drugs and significantly cutting cardiovascular risk. Strong expectations surround Scribe Therapeutics’ STX-1150, a US-developed therapy that lowers LDL (“bad”) cholesterol by epigenetically silencing the PCSK9 […]
Gene Editing Nears an End to Daily Cholesterol Meds Read More »









